ATC Group: N03AB02 Phenytoin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N03AB02 in the ATC hierarchy

Level	Code	Title
`1`	N	Nervous system
`2`	N03	Antiepileptics
`3`	N03A	Antiepileptics
`4`	N03AB	Hydantoin derivatives
`5`	N03AB02	Phenytoin

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
ORAL	Oral	0.3 g
PAREN	Parenteral	0.3 g

Active ingredients in N03AB02

Active Ingredient
Phenytoin
Phenytoin is effective in various animal models of generalised convulsive disorders, reasonably effective in models of partial seizures but relatively ineffective in models of myoclonic seizures. It appears to stabilise rather than raise the seizure threshold and prevents spread of seizure activity rather than abolish the primary focus of seizure discharge.

Related product monographs

Document	Type	Information Source
DILANTIN Extended-release capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)
DILANTIN INFATABS Chewable tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
DILANTIN-125 Oral suspension	MPI, US: SPL/PLR	FDA, National Drug Code (US)
EPANUTIN Oral suspension	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
EPANUTIN READY MIXED Solution for injection or infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)